You are being redirected because this document is part of your ASTM Compass® subscription.
    This document is part of your ASTM Compass® subscription.

    If you are an ASTM Compass Subscriber and this document is part of your subscription, you can access it for free at ASTM Compass
    Volume 49, Issue 6 (February 2021)

    A Safety Study for Long-Time Use of a Novel Pain Management Device, AT-04

    (Received 25 June 2020; accepted 18 September 2020)

    Published Online: 05 February 2021

    CODEN: JTEVAB

      Format Pages Price  
    PDF (170.96 KB) 7 $25   ADD TO CART

    Cite this document

    X Add email address send
    X
      .RIS For RefWorks, EndNote, ProCite, Reference Manager, Zoteo, and many others.   .DOCX For Microsoft Word



    Abstract

    Fibromyalgia is a common chronic pain disorder characterized by widespread pain and tenderness in mostly tendon attachments with unknown etiology. Treatment of fibromyalgia is mainly drug and other treatments, especially cognitive behavioral therapy and exercise therapy combined. However, drugs for fibromyalgia have, in general, broad adverse effects. Thus, an unmet medical need remains for effective therapeutic modalities for fibromyalgia. We have recently developed a new magnetic medical device (project code “AT”) that has alternating magnetic fields and stimulates the affected area for pain relief. In the pilot study, AT treatment (twice daily for 10 min) tended to reduce the mean NRS (Numerical Rating Scale) pain score. Moreover, we demonstrated long treatment (30 min) suppressed LPS-induced (Lipopolysaccharide-induced) mRNA IL-6 expression compared with 10-min treatment in vitro. These results assumed that long treatment has high efficiency. To evaluate the safety of long time (120 min/day) AT treatment for 12 weeks. Single center, prospective, open-label, single-arm, intervention study to demonstrate the safety of long-time use of AT in 5 healthy Japanese volunteers to 12 weeks. During the intervention period, all of the adverse events were measured. The represents of AT treatment was 99.8 % in 5 subjects. The average and median exposure time of the study device was 135 min per day and 132 min per day, respectively. There were 3 nonserious adverse events and no serious adverse events during this study. This study tested long-time use of AT among 5 healthy subjects in Japan and showed that it did not pose any significant safety concerns. Because there are in-house in vitro data suggesting that the longer exposure of AT achieves a greater effect, the result of this study may allow us to conduct further studies to confirm more effectiveness and safety of long-time use of AT in a larger scale of clinical trial.

    Author Information:

    Uchida, Takahiro
    Kasai Central Hospital, 7-10-3 Funabori, Tokyo,

    Japanese Organization for Medical Device Development, Inc., Tokyo,

    Tsuchiya, Akio
    Kasai Central Hospital, 7-10-3 Funabori, Tokyo,

    Mitsutake, Kazunori
    Peace of Mind Co., Ltd., Kumamoto,

    Kishita, Kaori
    Peace of Mind Co., Ltd., Kumamoto,

    Takaki, Kaori
    Peace of Mind Co., Ltd., Kumamoto,

    Guto, In
    Japanese Organization for Medical Device Development, Inc.Peace of Mind Co., Ltd., 2-8-6 Tokuo, TokyoKumamoto,

    Kishita, Iwao
    Peace of Mind Co., Ltd., Kumamoto,

    Oka, Hiroshi
    Tokyo Yaesu Clinic, Echizenya Bld 2F, Tokyo,


    Stock #: JTE20200406

    ISSN:0090-3973

    DOI: 10.1520/JTE20200406

    Author
    Title A Safety Study for Long-Time Use of a Novel Pain Management Device, AT-04
    Symposium ,
    Committee F04